Dual immunotherapy with ipilimumab-nivolumab is a preferred first-line option for patients regardless of BRAF status and has demonstrated superior efficacy compared with monotherapy with either nivolumab or pembrolizumab. However, it is associated with a higher risk for immune-related toxicities. Considerations in selection of immunotherapy include performance status, medical history, concomitant therapies, comorbidities, and patient compliance with proactive monitoring and management of adverse events.
Systemic targeted therapy (BRAF-MEK) is also a recommended first-line treatment option for patients with BRAF-mutant melanoma. Randomized clinical trials that compare first-line systemic targeted therapy (BRAF-MEK) with immunotherapy are ongoing.
Learn more about the treatment of metastatic melanoma.
Editor's Recommendations
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Adil Daud. Fast Five Quiz: Metastatic Melanoma - Medscape - Mar 15, 2023.
Comments